Showing posts with label Alzheimer's disease. Show all posts
Showing posts with label Alzheimer's disease. Show all posts

Wednesday, February 18, 2015

Air pollution affects children's memory, IQ: Study

Exposure to air pollution  can damage the brain,
a new study shows.
City smog lowers children's IQ.

This is among findings from a recent University of Montana study that found children living in cities with significant air pollution are at an increased risk for detrimental impacts to the brain, including short-term memory loss and lower IQ.

Findings by UM Professor Dr. Lilian Calderón-Garcidueñas, MA, MD, Ph.D., and her team of researchers reveal that children with lifetime exposures to concentrations of air pollutants above the current U.S. standards, including fine particulate matter, are at an increased risk for brain inflammation and neurodegenerative changes, including Alzheimer's and Parkinson's diseases.

Calderón-Garcidueñas' findings are detailed in a paper titled "Decreases in Short-Term Memory, IQ and Altered Brain Metabolic Rations in Urban Apolipoprotein ε4 Children Exposed to Air Pollution," which can be found online here.

The study found that clinically healthy children who live in a polluted environment and who also carry a gene - the apolipoprotein ε4 allele, already known to increase a person's risk of developing Alzheimer's disease - demonstrated compromised cognitive responses when compared with children carrying a gene with apolipoprotein ε3 allele.

Urban growth leads to environmental pollution

Metropolitan Mexico City is an example of extreme urban growth and serious environmental pollution, where 8 million children are involuntarily exposed to harmful concentrations of fine particulate matter in the air every day beginning at conception.

The study matched two groups of children living in Mexico City by multiple variables, including age, gender, socioeconomic status and education, among others.

They then compared children carrying the ε4 allele to children carrying the ε3 allele and found that those with the ε4 allele had three significant alterations.

They had short-term memory shortfalls, an IQ that while within the normal limits measured 10 points less, and changes in key metabolites in the brain that mirror those of people with Alzheimer's disease.

"The results add to growing data suggesting ε4 carriers could have a higher risk of developing early Alzheimer's disease if they reside in a polluted urban environment," Calderón-Garcidueñas said.

She said the study also raises concerns about important educational issues. Since Mexico City children mostly attend underprovided public schools, children do not build cognitive reserves that serve as a defense to pollution impacts.

"A IQ difference of 10 points will likely have a negative impact on academic and social issues, including bullying and teen delinquency," she said.

A serious public health issue

The authors argue that sustained exposures to urban air pollution result in cognitive underperformance and metabolic brain changes that could lead to an acceleration of neurodegenerative changes.

Air pollution is a serious public health issue, and exposures to concentrations of air pollutants at or above the current standards have been linked to neuroinflammation and neuropathology.

In the U.S. alone, 200 million people live in areas where pollutants such as ozone and fine particulate matter exceed the standards.

There are significant associations between exposures to particulate matter and increased mortality due to stroke, cardiovascular disease and respiratory events. The problem in children living in megacities like Mexico City is much worse.

"There is an urgent need to have a broader focus on APOE ε4 and air pollution interactions impacting children's brains, and their responses could provide new avenues toward the unprecedented opportunity for Alzheimer's disease prevention," Calderón-Garcidueñas said.

"We have a 50-year window of opportunity between the time urban children experience the detrimental effects we are describing here and when they will present with mild cognitive impairment and dementia. We need support for studying the current pediatric clinical and imaging evidence in highly exposed urban children. Our efforts should be aimed to identify and mitigate environmental factors influencing Alzheimer's disease."

Source: Press release via EurekAlert

Breathe fresher air indoors

AllerAir offers units in all sizes and
price ranges.
When the outdoor air is polluted, indoor air can become a health hazard as well - since contaminants can build up indoors and affect your health and well-being in the long term.

AllerAir's complete air purifiers with activated carbon, HEPA and optional UV address common ambient air concerns, including airborne chemicals, odors, fumes, particles, allergens and biological contaminants.

AllerAir offers mobile general purpose air purifiers as well as units that address specific concerns, including allergies and asthma, MCS, smoke, and much more.

For a free consultation, contact our team at 1-888-852-8247 or by writing to sales@allerair.com.

Thursday, October 17, 2013

In elderly, hardening of arteries linked to plaques in brain

Even for elderly people with no signs of dementia, those with hardening of the arteries are more likely to also have the beta-amyloid plaques in the brain that are a hallmark of Alzheimer's disease, according to a study published in the online issue of Neurology, the medical journal of the American Academy of Neurology.

"This is more evidence that cardiovascular health leads to a healthy brain," said study author Timothy M. Hughes, PhD, of the University of Pittsburgh.

The study involved 91 people with an average age of 87 who did not have dementia. Researchers took scans of the participants' brains to measure any plaques in the brain. The amount of stiffness in the participants' arteries was measured about two years later.

Half of all participants had beta-amyloid plaques. People with beta-amyloid plaques were more likely to have high systolic blood pressure, higher average blood pressure and higher arterial stiffness as measured with the brachial-ankle method. For every unit increase in brachial-ankle arterial stiffness, people were twice as likely to have beta-amyloid plaques in the brain.

Arterial stiffness was highest in people who had both amyloid plaques and white matter hyperintensities in the brain, or brain lesions.

"These two conditions may be a 'double-hit' that contributes to the development of dementia," Hughes said. "Compared to people who had low amounts of amyloid plaques and brain lesions, each unit of increase in arterial stiffness was associated with a two- to four-fold increase in the odds of having both amyloid plaques and a high amount of brain lesions."

Hughes noted that the relationship between arterial stiffness and amyloid plaque was not changed when regular resting blood pressure was taken into account. "This study adds to growing evidence that hardening of the arteries is associated with cerebrovascular disease that does not show symptoms. Now we can add Alzheimer's type lesions to the list," Hughes said.

--------------------------------------------------------
Exposure to air pollution can affect cardiovascular health. Reduce your exposure to pollutants by cleaning the air your breathe. AllerAir air cleaners remove 99.97% of airborne dust, particles and the chemicals and odors that other air cleaners leave behind. Connect with us to learn more www.allerair.com.

Wednesday, June 12, 2013

Drugs for hypertension, depression, and insomnia may influence the onset and progression of Alzheimer's disease

photo:freedigitalphotos.com
Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center.

Led by Giulio Maria Pasinetti, MD, PhD, a research team used a computer algorithm to screen 1,600 commercially-available medications to assess their impact on the brain accumulation of beta-amyloid, a protein abnormally accumulated in the brain of Alzheimer's disease and implicated in neurodegeneration.

They found that currently-available medications prescribed for conditions such as hypertension, depression, and insomnia were found to either to block or to enhance the accumulation of beta-amyloid, the component of amyloid plaques.

"This line of investigation will soon lead to the identification of common medications that might potentially trigger conditions associated with the prevention, or conversely the onset, of Alzheimer's disease," said Dr. Pasinetti. "They may be a novel reference for physicians to consider when prescribing the most appropriate drug, particularly in subjects at high risk for Alzheimer's disease."

To validate the screening protocol, Dr. Pasinetti and his colleagues administered these drugs in mice that were genetically engineered to develop the hallmark amyloid plaques associated with Alzheimer's disease. After six months of treatment with blood pressure medicines, amyloid plaques and neurodegeneration were significantly reduced in the mice. One such medicine was Carvedilol, now under clinical investigation in Alzheimer 's disease with the intent to slow down memory deterioration.

"In recent years, amyloid plaques have become one of the main focal points in the search to understand and to treat Alzheimer's disease," said Dr. Pasinetti. "Thus, identifying novel drug treatments that prevent harmful beta-amyloid generation will help in the development of treatments for Alzheimer's disease. For example, one very exciting finding of our study is that Carvedilol, already approved for treatment of hypertension, may immediately become a promising drug for the treatment of Alzheimer's as well."

The authors discuss the limitations of the research, noting that studies must be immediately verified in human-safety studies that examine the effects of the drugs independent of the original indication. Dr. Pasinetti hopes these findings will lead to multiple clinical trials in the future to identify preventive drugs, which will need to be prescribed at tolerable dosages.

"If we can repurpose drugs currently used for different indications, such as lowering blood pressure, this could have dramatic implications for this population," said Dr. Pasinetti.

The findings are published online in the journal PLoS One. 

--------------------------------------------------------------------------
For more stories on better health, pollution, chemical exposure and improving your indoor air quality visit www.allerair.com or call to speak to an air quality expert about improving the air in your home 1-888-852-8247. 

Monday, March 11, 2013

Sleep loss precedes Alzheimer’s symptoms

Sleep is disrupted in people who likely have early Alzheimer’s disease but do not yet have the memory loss or other cognitive problems characteristic of full-blown disease, researchers at Washington University School of Medicine in St. Louis report March 11 in JAMA Neurology.

The finding confirms earlier observations by some of the same researchers. Those studies showed a link in mice between sleep loss and brain plaques, a hallmark of Alzheimer’s disease. Early evidence tentatively suggests the connection may work in both directions: Alzheimer’s plaques disrupt sleep, and lack of sleep promotes Alzheimer’s plaques.

“This link may provide us with an easily detectable sign of Alzheimer’s pathology,” says senior author David M. Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of Washington University’s Department of Neurology. “As we start to treat people who have markers of early Alzheimer’s, changes in sleep in response to treatments may serve as an indicator of whether the new treatments are succeeding.”

Sleep problems are common in people who have symptomatic Alzheimer’s disease, but scientists recently have begun to suspect that they also may be an indicator of early disease. The new paper is among the first to connect early Alzheimer’s disease and sleep disruption in humans.

For the new study, researchers recruited 145 volunteers from the University’s Charles F. and Joanne Knight Alzheimer’s Disease Research Center. All of the volunteers were 45 to 75 years old and cognitively normal when they enrolled.

As a part of other research at the center, scientists already had analyzed samples of the volunteers’ spinal fluids for markers of Alzheimer’s disease. The samples showed that 32 participants had preclinical Alzheimer’s disease, meaning they were likely to have amyloid plaques present in their brains but were not yet cognitively impaired.

Participants kept daily sleep diaries for two weeks, noting the time they went to bed and got up, the number of naps taken on the previous day, and other sleep-related information.

The researchers tracked the participants’ activity levels using sensors worn on the wrist that detected the wearer’s movements.

“Most people don’t move when they’re asleep, and we developed a way to use the data we collected as a marker for whether a person was asleep or awake,” says first author Yo-El Ju, MD, assistant professor of neurology. “This let us assess sleep efficiency, which is a measure of how much time in bed is spent asleep.”

Participants who had preclinical Alzheimer’s disease had poorer sleep efficiency (80.4 percent) than people without markers of Alzheimer’s (83.7 percent). On average, those with preclinical disease were in bed as long as other participants, but they spent less time asleep. They also napped more often.

“When we looked specifically at the worst sleepers, those with a sleep efficiency lower than 75 percent, they were more than five times more likely to have preclinical Alzheimer’s disease than good sleepers,” Ju says.

Ju and her colleagues are following up with studies in younger participants who have sleep disorders.

“We think this may help us get a better feel for the way this connection flows — does sleep loss drive Alzheimer’s, does Alzheimer’s lead to sleep loss, or is it a combination?” Ju says. “That will help us determine whether we can change the course of disease with pharmaceuticals or other treatments.”

--------------------------------------------------------------------------
For more stories on health, pollution, chemical exposure and improving your indoor air quality visit www.allerair.com or call to speak to an air quality expert about improving the air in your home 1-888-852-8247.

Tuesday, December 11, 2012

Researchers make key discovery in fight against Alzheimer's disease


Medical researchers at the University of Alberta, Canada have discovered a drug intended for diabetes appears to restore memory in Alzheimer's brain cells.

Jack Jhamandas, a researcher with the Faculty of Medicine & Dentistry at the U of A, is the principal investigator with the team whose research results were recently published in the peer-reviewed publication The Journal of Neuroscience. He works in the Division of Neurology.

The team took brain tissue from animal models with Alzheimer's disease and tested the tissue in the lab, looking specifically at the cells' memory capacity. When brain cells are shocked by a barrage of electrical impulses, the cells "remember" the experience and this is a typical way to test or measure memory in the lab setting.

Amyloid protein, which is found in abnormally large amounts in the memory and cognition parts of the brains of Alzheimer's patients, diminishes memory. A sister protein, known as amylin, which comes from the pancreas of diabetic patients, has the same impact on memory cells.

Jhamandas and his team demonstrated last year that a diabetes drug that never made it to market, known as AC253, could block the toxic effects of amyloid protein that lead to brain cell death.

In the lab, Jhamandas and his teammates, which included Ryoichi Kimura, a visiting scientist from Japan, tested the memory of normal brain cells and those with Alzheimer's—both from animal models. When the drug AC253 was given to brain cells with Alzheimer's and the shock memory tests were redone, memory was restored to levels similar to those in normal cells.

"This is very important because it tells us that drugs like this might be able to restore memory, even after Alzheimer's disease may have set in," says Jhamandas.

His team is continuing their research in this area and wants to see if the drug, when given before symptoms appear, can "stop the impairment of behaviour and cognition altogether in animals destined to develop Alzheimer's," says Jhamandas. Their continued research tests will take a least a year to complete.

He noted it is difficult for AC253 to cross the brain barrier, so research teams in pharmaceutical companies would need to design a similar drug that is easier to penetrate brain cells. Jhamandas says if the tests are successful, he thinks clinical trials could start within about five years, but he stressed that further testing needs to be done before such trials can occur.

"I think what we discovered may be part of the solution, but I can't say it will be the solution. There is a long list of drugs and approaches that haven't panned out as expected in the fight against Alzheimer's. I don't think one drug or approach will solve Alzheimer's disease because it's a complicated disease, but I am cautiously optimistic about our discovery and its implications."